Health Canada Accepts New Drug Submission for Trofinetide Acadia Pharmaceuticals is pleased to share that Health Canada has accepted their New Drug Submission (NDS) of trofinetide for the treatment of Rett Syndrome. Moreover, the treatment has been granted Priority Review to… Read More
Health Canada Accepts a New Drug Submission
Leave a Comment
Last Updated: 04/24/2024 by Steve
Health Canada Accepts New Drug Submission for Trofinetide Acadia Pharmaceuticals is pleased to share that Health Canada has accepted their New Drug Submission (NDS) of trofinetide for the treatment of Rett Syndrome. Moreover, the treatment has been granted Priority Review to… Read More
Parent Survey
Leave a Comment
Last Updated: 08/08/2023 by admin
Karen Congram is a graduate student in the Faculty of Education at Wilfrid Laurier University. She is conducting a study to examine the barriers to full participation and learning for students with complex communication needs in Ontario public schools from… Read More
Acadia acquires global rights to Trofinetide
Leave a Comment
Last Updated: 08/28/2023 by admin
Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome – Expanded agreement follows Acadia’s April 2023 U.S. launch of DAYBUE™ (trofinetide) as the first and only… Read More